GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Employees: 1,000
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
147% more call options, than puts
Call options by funds: $62.7M | Put options by funds: $25.3M
84% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 32
44% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 59
39% more capital invested
Capital invested by funds: $1.81B [Q4 2024] → $2.51B (+$701M) [Q1 2025]
20% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 12 (+2) [Q1 2025]
15.33% more ownership
Funds ownership: 85.66% [Q4 2024] → 100.99% (+15.33%) [Q1 2025]
13% more funds holding
Funds holding: 199 [Q4 2024] → 224 (+25) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$80
23%
downside
Avg. target
$102
1%
downside
High target
$115
11%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Wells Fargo Brandon Couillard | 8%downside $95 | Equal-Weight Maintained | 30 Jul 2025 |
Piper Sandler David Westenberg | 6%upside $110 | Overweight Initiated | 9 Jul 2025 |
Guggenheim Subbu Nambi | 11%upside $115 | Buy Maintained | 30 Jun 2025 |
Jefferies Tycho Peterson | 23%downside $80 | Buy Upgraded | 9 May 2025 |
TD Securities Dan Brennan | 6%upside $110 | Buy Maintained | 1 May 2025 |
Financial journalist opinion
Based on 32 articles about WGS published over the past 30 days
Neutral
GlobeNewsWire
1 hour ago
GeneDx Holdings Corp. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, July 30, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses
Positive
CNBC Television
9 hours ago
GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options
Katherine Stueland, GeneDx CEO, joins 'Squawk Box' to discuss diagnosing children with rare diseases, cost structure of the tests, the fight against rare diseases, company growth outlook, deployment of AI, and more.
Neutral
GlobeNewsWire
22 hours ago
GENEDX (WGS) ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin (LMT) To Contact Him Directly To Discuss Their Options
Positive
The Motley Fool
23 hours ago
Why GeneDx Holdings Stock Blasted 8% Higher Today
The stock of genetic testing company GeneDx Holdings (WGS 8.09%) was quite the hot item on the second trading day of the week. After the company published an encouraging second-quarter earnings report, investors piled into its shares to boost them to a more than 8% gain.
Neutral
Seeking Alpha
1 day ago
GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Katherine A. Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Sabrina Dunbar - Corporate Participant Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Daniel Gregory Brennan - TD Cowen, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Subhalaxmi T.
Neutral
GlobeNewsWire
1 day ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Positive
Zacks Investment Research
1 day ago
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Positive
Zacks Investment Research
1 day ago
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to a loss of $0.11 per share a year ago.
Neutral
Business Wire
1 day ago
GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the second quarter of 2025.
Neutral
PRNewsWire
1 day ago
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
NEW YORK , July 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Charts implemented using Lightweight Charts™